



## Therapeutic Strategies for Diabetic Kidney Disease

Guest Editors:

**Dr. Keiichiro Matoba**

Division of Diabetes,  
Endocrinology, and Metabolism,  
Department of Internal Medicine,  
The Jikei University School of  
Medicine, 3-25-8, Nishishinbashi,  
Minato-ku, Tokyo 105-8461,  
Japan

**Dr. Naga Samji**

Hospitalist in Tennova Health  
Center, Cleveland, TN, USA

Deadline for manuscript  
submissions:

**closed (25 May 2022)**

### Message from the Guest Editors

Diabetic kidney disease (DKD) is a worldwide public health concern. It is the leading cause of the end-stage renal disease (ESRD) and is strongly associated with a high cardiovascular death rate in patients with diabetes. The pathological significance of activated renin-angiotensin system (RAS) and hemodynamic changes is becoming increasingly evident, and a large number of diabetic patients are treated with RAS and/or SGLT2 inhibitors. While currently approved, these agents can retard but not completely prevent the progression to ESRD and cardiovascular events. Given the importance of DKD as a major risk factor for macrovascular complications, it is important to understand how this disease progresses and how the vascular disease is involved.

In this Special Issue of Diabetology, we invite researchers to submit original research articles as well as review articles focusing on the molecular mechanisms of DKD. Contributions demonstrating original therapeutic opportunities or strategies for reducing cardiovascular complications are also encouraged.

